MR VOLUMETRY FOR MONITORING INTRAMUSCULAR BROMOCRIPTINE TREATMENT IN MACROPROLACTINOMAS

被引:7
作者
BENESCH, H
FELBER, SR
FINKENSTEDT, G
KREMSER, C
STOCKHAMMER, G
AICHNER, FT
机构
[1] UNIV INNSBRUCK, DEPT MAGNET RESONANCE TOMOG & SPECT, A-6020 INNSBRUCK, AUSTRIA
[2] UNIV INNSBRUCK, DEPT INTERNAL MED, ENDOCRINOL UNIT, A-6020 INNSBRUCK, AUSTRIA
[3] UNIV INNSBRUCK, DEPT NEUROL, A-6020 INNSBRUCK, AUSTRIA
关键词
PITUITARY GLAND; NEOPLASMS; BRAIN; VOLUMETRY; MAGNETIC RESONANCE IMAGING;
D O I
10.1097/00004728-199511000-00005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To assess volumetric changes of pituitary prolactinomas, we applied a threshold-based segmentation algorithm in two patients during intramuscular bromocriptine treatment. Materials and Methods: Tumor volumes were calculated from contiguous slices of a 3D GE sequence and from conventional SE images. Results: After a single 50 mg i.m. bromocriptine administration, the prolactinoma volumes decreased by 25 and 35% within 7 and 11 days, respectively. Volume calculations from 3D GE images were more accurate than calculations from 3 mm 2D SE images, especially for smaller tumors. A decrease of prolactinoma size was paralleled by a decrease of serum prolactin levels and correlated with an improvement of visual field and endocrine function in both patients. The end of the bromocriptine effect was indicated by a reincreasing tumor volume, which was observed after 30 days in the first patient and after 43 days in the second patient. Conclusion: Our results suggest that MR volumetry represents a useful tool to monitor changes of prolactinoma volume during bromocriptine treatment and may improve the clinical management of these patients.
引用
收藏
页码:866 / 870
页数:5
相关论文
共 14 条
[1]   BROMOCRIPTINE TREATMENT REDUCES THE CELL-SIZE IN HUMAN MACROPROLACTINOMAS - A MORPHOMETRIC STUDY [J].
BASSETTI, M ;
SPADA, A ;
PEZZO, G ;
GIANNATTASIO, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 58 (02) :268-273
[2]   TREATMENT OF MACROPROLACTINOMAS WITH THE LONG-ACTING AND REPEATABLE FORM OF BROMOCRIPTINE - A REPORT ON 29 CASES [J].
BECKERS, A ;
PETROSSIANS, P ;
ABS, R ;
FLANDROY, P ;
STADNIK, T ;
DELONGUEVILLE, M ;
LANCRANJAN, I ;
STEVENAERT, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (01) :275-280
[3]   PARENTERAL BROMOCRIPTINE IN THE TREATMENT OF HORMONALLY ACTIVE PITUITARY-TUMORS [J].
BENKER, G ;
GIESHOFF, B ;
FREUNDLIEB, O ;
WINDECK, R ;
SCHULTE, HM ;
LANCRANJAN, I ;
REINWEIN, D .
CLINICAL ENDOCRINOLOGY, 1986, 24 (05) :505-513
[4]  
BESSER M, 1993, ACTA ENDOCRINOL-COP, V129, P27
[5]   LONG-TERM THERAPY OF PATIENTS WITH MACROPROLACTINOMA USING REPEATABLE INJECTABLE BROMOCRIPTINE [J].
CICCARELLI, E ;
MIOLA, C ;
GROTTOLI, S ;
AVATANEO, T ;
LANCRANJAN, I ;
CAMANNI, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (02) :484-488
[6]   NECROTIC CHANGES IN PROLACTINOMAS AFTER LONG-TERM ADMINISTRATION OF BROMOCRIPTINE [J].
GEN, M ;
UOZUMI, T ;
OHTA, M ;
ITO, A ;
KAJIWARA, H ;
MORI, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 59 (03) :463-470
[7]   CONTROL OF PROLACTIN-SECRETING MACROADENOMAS WITH PARENTERAL, LONG-ACTING BROMOCRIPTINE IN 30 PATIENTS TREATED FOR UP TO 3 YEARS [J].
HAASE, R ;
JASPERS, C ;
SCHULTE, HM ;
LANCRANJAN, I ;
PFINGSTEN, H ;
ORRIFEND, M ;
REINWEIN, D ;
BENKER, G .
CLINICAL ENDOCRINOLOGY, 1993, 38 (02) :165-176
[8]   TEMPORAL-LOBE VOLUME MEASUREMENT FROM MR IMAGES - ACCURACY AND LEFT-RIGHT ASYMMETRY IN NORMAL PERSONS [J].
JACK, CR ;
GEHRING, DG ;
SHARBROUGH, FW ;
FELMLEE, JP ;
FORBES, G ;
HENCH, VS ;
ZINSMEISTER, AR .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1988, 12 (01) :21-29
[9]  
JAQUET P, 1993, ACTA ENDOCRINOL-COP, V129, P31
[10]   A COMPARISON OF THE EFFICACY AND SAFETY OF PERGOLIDE AND BROMOCRIPTINE IN THE TREATMENT OF HYPERPROLACTINEMIA [J].
LAMBERTS, SWJ ;
QUIK, RFP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (03) :635-641